Celiprolol in hypertension.
Celiprolol is a third-generation, beta-adrenoceptor antagonist with ancillary pharmacologic properties that are potentially advantageous in the treatment of hypertension. Celiprolol provides 24-hour control of blood pressure and in formal clinical trials has been found superior to a placebo and of equal efficacy to other commonly used beta-blocking drugs. It has also been found to be equally as effective as enalapril in lowering the resting blood pressure and superior in controlling the increases in blood pressure and heart rate during exercise. Celiprolol is known to exert a beneficial effect on the atheroprotective components of the risk factors for coronary heart disease, such as cholesterol triglyceride, and fibrinogen. Therefore the primary attributes of beta-blockade are uniquely advanced by celiprolol's ancillary pharmacologic activities.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D017272:Celiprolol; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D010919:Placebos; D011412:Propanolamines / Q000627:therapeutic use*; D011897:Random Allocation
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D010919:Placebos; D011412:Propanolamines; D017272:Celiprolol